Abstract
Eribulin mesylate (E7389) is a synthetic analog of the marine macrolide halichondrin B, which acts as a novel microtubule modulator with a distinct mechanism of action. Two eribulin mesylate phase 1 studies exploring weekly and 3-weekly schedules are reported in this issue. These trials show linear pharmacokinetics, a toxicity profile consisting in neutropenia and fatigue, and early hints of antitumor activity. In this commentary we give a brief historical perspective of the halichondrins and put into context eribulin mesylate as a novel tubulin modulator.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Furans / administration & dosage
-
Furans / adverse effects
-
Furans / therapeutic use*
-
Humans
-
Ketones / administration & dosage
-
Ketones / adverse effects
-
Ketones / therapeutic use*
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Tubulin / metabolism*
-
Tubulin Modulators / administration & dosage
-
Tubulin Modulators / adverse effects
-
Tubulin Modulators / therapeutic use*
Substances
-
Antineoplastic Agents
-
Furans
-
Ketones
-
Tubulin
-
Tubulin Modulators
-
eribulin